A LASSO-based nomogram for predicting sarcopenia-related nutritional risk in esophageal cancer patients: model development, validation, and an interactive clinical decision tool
The model demonstrates favorable discrimination, calibration, and clinical utility, and provides a convenient and precise tool for early screening and individualized intervention of sarcopenia in patients with esophageal cancer.
Abstract
Objective This study aims to construct an interpretable predictive model for esophageal cancer sarcopenia-related nutritional risk based on multidimensional clinical indicators and develop an interactive clinical decision support system. Methods The study cohort comprised 202 patients with a confirmed diagnosis of esophageal cancer who were retrospectively recruited from Taikang Xianlin Drum Tower Hospital. The study period spanned from January 2023 to December 2025. The sample was split into training and validation datasets (7:3), respectively. Sarcopenia nutritional risk was defined as NRS-2002 score ≥3. Predictors were screened using LLogistic and LASSO regression to construct a model. Model performance was evaluated using ROC, calibration, decision curve analysis (DCA), and CIC curves. Model interpretability was analyzed using SHAP values. An interactive online prediction system was developed based on R Shiny. Results Age, sex, BMI, diabetes, intervention, prothrombin time (PT), and clinical stage (cStage) were predictors of sarcopenia-related nutritional risk. The AUC was 0.864 (0.778–0.940) in the training set and 0.802 (0.696–0.898) in the validation set. The calibration curves showed satisfactory goodness of fit (P > 0.05), and DCA indicated clinical net benefit within the threshold range of 0.05–0.70. SHAP analysis revealed that BMI, PT, and gender were key contributing factors. The interactive prediction system “Sarcopenia Intelligence” was successfully developed (https://ytky622.shinyapps.io/Sarcopenia_Predictor_2026/). Conclusion The model demonstrates favorable discrimination, calibration, and clinical utility. Combined with SHAP interpretability and the interactive system, it provides a convenient and precise tool for early screening and individualized intervention of sarcopenia in patients with esophageal cancer.
Using six readily available clinical features, the logistic regression model shows robust generalizability across populations, enabling timely interventions to mitigate sarcopenia-related complications in diabetic patients.
Ming-Jie Tang, Shi-Yi Zheng, Hang Xu et al.· Frontiers in Medicine· 0 citations
The externally validated random forest model showed acceptable discriminative performance and provided an interpretable assessment of the contributions of individual features, which may support static early risk stratification of ENAD among critically ill patients receiving enteral nutrition.
Yu-Hong Wang, Wei Hu, Cai-Yue Xu et al.· Frontiers in Nutrition· 0 citations
Existing prediction models for sarcopenia or low muscle mass in T2DM patients show promising discrimination, but limitations in analysis methods, reporting and external validation may affect their robustness and generalisability.
Wei-Jun Tang, Rui Luo, Yue Luo et al.· Journal of diabetes and its...· 0 citations
To develop and validate a nomogram incorporating nutritional risk for predicting 31-day unplanned readmission in patients with type 2 diabetes mellitus (T2DM).
This retrospective study included 1,627 T2DM patients. A nomogram was constructed using least absolute shrinkage and selection operator (LASSO) reg...
Jing Cao, Qiu-Mei Shi, Zi-Kai Yu et al.· Frontiers in Nutrition· 0 citations
To screen the independent risk factors for enteral nutrition intolerance (ENI) in elderly comorbid patients with sarcopenia, and to establish and validate a clinical prediction model for individualized risk assessment and targeted intervention.
A total of 202 elderly comorbid patients with sarcopenia recei...
Hao Wang, Rui-Chun Lu· Frontiers in Nutrition· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.